Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is a double-blind,randomized,placebo-controlled study to evaluate the efficacy and
safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease
2019(COVID-19). A total of about 1336 subjects are planned to be enrolled. The subjects will
be randomized in a 1:1 ratio to FB2001 group or placebo group while both receiving standard
of care treatment.